SML2363

AST487

≥98% (HPLC)

• Synonym(s): 1-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(4-(6-(methylamino)pyrimidin-4-yloxy)phenyl)urea, AST 487, AST-487, N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-N′-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea, NVP-AST 487, NVP-AST-487, NVP-AST487
• Empirical Formula (Hill Notation): C₂₆H₃₀F₃N₇O₂
• CAS Number: 630124-46-8
• Molecular Weight: 529.56
• UNSPSC Code: 12352200
• MDL number: MFCD11983171
• NACRES: NA.21
• Assay: ≥98% (HPLC)
• Form: powder

Properties

• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: CCN1CCN(CC2=C(C(F)(F)F)C=C(NC(NC3=CC=C(OC4=NC=NC(NC)=C4)C=C3)=O)C=C2)CC1
• InChI: 1S/C26H30F3N7O2/c1-3-35-10-12-36(13-11-35)16-18-4-5-20(14-22(18)26(27,28)29)34-25(37)33-19-6-8-21(9-7-19)38-24-15-23(30-2)31-17-32-24/h4-9,14-15,17H,3,10-13,16H2,1-2H3,(H,30,31,32)(H2,33,34,37)
• InChI key: ODPGGGTTYSGTGO-UHFFFAOYSA-N

Description

Biochem/physiol Actions

AST487 is an orally available type II tyrosine kinase inhibitor (TKI) that exhibits potent antiproliferation activity against FLT3, RET, PDGFR1, but not BRAF, oncogenic fusions/mutations-driven growth (IC50 = 1.8 nM/FLT3-ITD BaF3, 5.1 nM/FLT3 D835I BaF3, 9-27 nM/TEL-PDGFR1 & PTC3-RET BaF3, <1 nM/FLT3-ITD-expressing MV4-11 &amp; MOLM-13) via binding/stablizing target kinases in the inactive “DFG-out” conformation. AST487 effectively suppresses RET- (NIH3T3-RETC634W & human medullary thyroid cancer (MTC) TT cells) and FLT3-ITD-driven (MV4-11) tumor growth in mice in vivo (20-50 mg/kg/day p.o.).

Orally active, type II tyrosine kinase inhibitor against FLT3, RET, and PDGFR1 oncogenic fusions/mutations-driven growth in vitro and in vivo.

AST487 is a N,N′-diphenyl urea, which inhibits growth and calcitonin gene expression in medullary thyroid cancer cells.

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable